- Home
- CKPT vs FLC Comparison
CKPT vs FLC Comparison
Compare CKPT & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- FLC
- Stock Information
- Founded
- CKPT 2014
- FLC 2003
- Country
- CKPT United States
- FLC United States
- Employees
- CKPT N/A
- FLC N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- CKPT Health Care
- FLC Finance
- Exchange
- CKPT Nasdaq
- FLC Nasdaq
- Market Cap
- CKPT 214.4M
- FLC 180.6M
- IPO Year
- CKPT 2017
- FLC N/A
- Fundamental
- Price
- CKPT $3.61
- FLC $16.69
- Analyst Decision
- CKPT Strong Buy
- FLC
- Analyst Count
- CKPT 3
- FLC 0
- Target Price
- CKPT $10.33
- FLC N/A
- AVG Volume (30 Days)
- CKPT 2.4M
- FLC 37.8K
- Earning Date
- CKPT 11-12-2024
- FLC 01-01-0001
- Dividend Yield
- CKPT N/A
- FLC 6.64%
- EPS Growth
- CKPT N/A
- FLC N/A
- EPS
- CKPT N/A
- FLC N/A
- Revenue
- CKPT $47,000.00
- FLC N/A
- Revenue This Year
- CKPT N/A
- FLC N/A
- Revenue Next Year
- CKPT $151,162.55
- FLC N/A
- P/E Ratio
- CKPT N/A
- FLC N/A
- Revenue Growth
- CKPT N/A
- FLC N/A
- 52 Week Low
- CKPT $1.38
- FLC $12.62
- 52 Week High
- CKPT $4.50
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- CKPT 41.64
- FLC 43.75
- Support Level
- CKPT $2.98
- FLC $16.41
- Resistance Level
- CKPT $4.44
- FLC $16.95
- Average True Range (ATR)
- CKPT 0.42
- FLC 0.16
- MACD
- CKPT -0.10
- FLC -0.02
- Stochastic Oscillator
- CKPT 25.66
- FLC 38.71
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.